AC Immune SA logo
AC Immune SA ACIU
$ 2.7 -2.17%

Annual report 2025
added 03-21-2026

report update icon

AC Immune SA Balance Sheet 2011-2026 | ACIU

Annual Balance Sheet AC Immune SA

2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Net Debt

- - -191 M -156 M -124 M -152 M -76.5 M -3.31 M - - -

Long Term Debt

- - - - - - 1.81 M 186 K 395 K - - - - - -

Long Term Debt Current

852 K 1.03 M 672 K 548 K 570 K 443 K 442 K - - - - - - - -

Total Non Current Liabilities

- - - - - 9.24 M 9.3 M 5.85 M 5.42 M 3.8 M 2.79 M 2.41 M - - -

Total Liabilities

109 M 119 M 22.2 M 16.9 M 29.5 M 23.3 M 26.8 M 18.9 M 15.2 M 13.7 M 8.89 M 6.83 M - - -

Deferred Revenue

- - - - - 306 K 4.48 M 351 K 355 K 521 K - 205 K - - -

Retained Earnings

- - - - - -133 M -75.5 M -122 M -72.6 M -46.9 M -40.4 M -60.5 M - - -

Total Assets

154 M 231 M 183 M 186 M 261 M 239 M 299 M 197 M 132 M 156 M 79.9 M 30.3 M - - -

Cash and Cash Equivalents

26.8 M 36.3 M 78.5 M 31.6 M 82.2 M 161 M 194 M 156 M 124 M 152 M 76.5 M - - - -

Book Value

44.9 M 112 M 161 M 169 M 232 M 215 M 272 M 178 M 117 M 142 M 71 M 23.5 M - - -

Total Shareholders Equity

- - - - - 215 M 272 M 178 M 117 M 142 M 71 M - - - -

All numbers in CHF currency

Quarterly Balance Sheet AC Immune SA

2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Long Term Debt

- - - - 2.34 M - - - 1.78 M - - - 1.81 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Total Non Current Liabilities

- - - - 9.44 M - - - 9.24 M - - - 9.3 M - - - 5.85 M - - - 5.42 M - - - 3.8 M - - - - - - - - - - - - - - - - - - - - - - -

Total Liabilities

- - - - 29.5 M - - - 23.3 M - - - 26.8 M - - - 18.9 M - - - 15.2 M - - - 13.7 M - - - - - - - - - - - - - - - - - - - - - - -

Retained Earnings

- - - - -201 M - - - -133 M - - - -75.5 M - - - -122 M - - - -72.6 M - - - -46.9 M - - - - - - - - - - - - - - - - - - - - - - -

Total Assets

- - - - 261 M - - - 239 M - - - 299 M - - - 197 M - - - 132 M - - - 156 M - - - - - - - - - - - - - - - - - - - - - - -

Cash and Cash Equivalents

- - - - 82.2 M - - - 161 M - - - 194 M - - - 156 M - - - 124 M - - - 152 M - - - 76.5 M - - - 3.31 M - - - - - - - - - - - - - - -

Book Value

- - - - 232 M - - - 215 M - - - 272 M - - - 178 M - - - 117 M - - - 142 M - - - - - - - - - - - - - - - - - - - - - - -

Total Shareholders Equity

- - - - 232 M - - - 215 M - - - 272 M - - - 178 M - - - 117 M - - - 142 M - - - 71 M - - - 23.5 M - - - - - - - - - - - - - - -

All numbers in CHF currency

Balance Sheet is a fundamental financial report of AC Immune SA, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.

For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.

Features of balance sheet analysis
  • Vertical and horizontal analysis
    Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods.
  • Asset quality
    It is important to evaluate not only the amount of assets but also their liquidity and realizability.
  • Accounting for off-balance sheet liabilities
    Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.

Balance sheet of other industry stocks – Biotechnology

Issuer Price % 24h Market Cap Country
BioNTech SE BioNTech SE
BNTX
$ 91.28 0.11 % $ 27.2 B germanyGermany
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
I-Mab I-Mab
IMAB
- - $ 866 M chinaChina
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
- - $ 40.3 B usaUSA
Genfit SA Genfit SA
GNFT
- 2.54 % $ 160 B franceFrance
Biophytis SA Biophytis SA
BPTS
- -13.47 % $ 169 M franceFrance
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
- -1.52 % $ 24.7 M usaUSA
Acorda Therapeutics Acorda Therapeutics
ACOR
- -24.86 % $ 820 K usaUSA
Advaxis Advaxis
ADXS
- -9.65 % $ 45.9 M usaUSA
Adverum Biotechnologies Adverum Biotechnologies
ADVM
- - $ 86.2 M usaUSA
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
- - - russiaRussia
Aeterna Zentaris Aeterna Zentaris
AEZS
- 5.93 % $ 314 M canadaCanada
AgeX Therapeutics AgeX Therapeutics
AGE
- -10.17 % $ 12.2 K usaUSA
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
- - $ 1.01 B usaUSA
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
- - $ 26.5 M usaUSA
AIkido Pharma AIkido Pharma
AIKI
- 1.93 % $ 17.4 M usaUSA
Aptose Biosciences Aptose Biosciences
APTO
- -45.71 % $ 1.2 M canadaCanada
Akero Therapeutics Akero Therapeutics
AKRO
- - $ 3.67 B usaUSA
CureVac N.V. CureVac N.V.
CVAC
- - $ 867 M germanyGermany
Akari Therapeutics, Plc Akari Therapeutics, Plc
AKTX
$ 3.54 -20.81 % $ 238 B britainBritain
Akouos Akouos
AKUS
- 0.23 % $ 488 M usaUSA
Allakos Allakos
ALLK
- - $ 28.6 M usaUSA
Allena Pharmaceuticals Allena Pharmaceuticals
ALNA
- 3.16 % $ 1.9 M usaUSA
Alnylam Pharmaceuticals Alnylam Pharmaceuticals
ALNY
$ 330.34 3.6 % $ 43.3 B usaUSA
Alpine Immune Sciences Alpine Immune Sciences
ALPN
- - $ 2.17 B usaUSA
Aileron Therapeutics Aileron Therapeutics
ALRN
- 10.36 % $ 9.8 M usaUSA
AlloVir AlloVir
ALVR
- 4.14 % $ 49.1 M usaUSA
Evogene Ltd. Evogene Ltd.
EVGN
$ 0.79 1.22 % $ 27.9 M israelIsrael
Atreca Atreca
BCEL
- -11.76 % $ 5.79 M usaUSA
Ampio Pharmaceuticals Ampio Pharmaceuticals
AMPE
- -11.43 % $ 502 K usaUSA
argenx SE argenx SE
ARGX
$ 748.25 0.25 % $ 25 B niderlandNiderland
Завод ДИОД Завод ДИОД
DIOD
- - - russiaRussia
Фармсинтез Фармсинтез
LIFE
- - - russiaRussia
Applied Molecular Transport Applied Molecular Transport
AMTI
- - $ 10.1 M usaUSA
Aptorum Group Limited Aptorum Group Limited
APM
$ 0.89 -4.33 % $ 4.85 M chinaChina
Applied Therapeutics Applied Therapeutics
APLT
- - $ 8.42 M usaUSA
Aptinyx Aptinyx
APTX
- -39.0 % $ 4.57 M usaUSA
Teligent, Inc. Teligent, Inc.
TLGT
- -13.85 % $ 16.1 M usaUSA
AbbVie AbbVie
ABBV
$ 206.69 -1.01 % $ 366 B usaUSA
Aquestive Therapeutics Aquestive Therapeutics
AQST
$ 4.09 -0.97 % $ 437 M usaUSA
Aravive Aravive
ARAV
- -13.39 % $ 1.45 M usaUSA
Viela Bio, Inc. Viela Bio, Inc.
VIE
- - $ 2.91 B usaUSA
AbCellera Biologics AbCellera Biologics
ABCL
$ 3.39 -3.69 % $ 1.01 B canadaCanada
Arcturus Therapeutics Holdings Arcturus Therapeutics Holdings
ARCT
$ 8.22 2.37 % $ 225 M israelIsrael
Ardelyx Ardelyx
ARDX
$ 5.97 0.51 % $ 1.44 B usaUSA
Genmab A/S Genmab A/S
GMAB
$ 27.75 0.91 % $ 17.6 B danmarkDanmark
Cerevel Therapeutics Holdings Cerevel Therapeutics Holdings
CERE
- - $ 7.29 B usaUSA
Grifols, S.A. Grifols, S.A.
GRFS
$ 8.23 -0.12 % $ 6.83 B spainSpain
Akebia Therapeutics Akebia Therapeutics
AKBA
$ 1.32 -4.35 % $ 339 M usaUSA